The trial focused on early-stage disease that hadn’t spread beyond the gland
Month: April 2016
Preliminary study finds more reason to improve your diet
In a small clinical trial of people with an inherited condition that greatly increases the risk of developing gastrointestinal cancers, a two-drug combination has been shown to shrink duodenal polyps, precursor lesions for cancer, raising the possibility that the regimen could lower the risk of duodenal cancer.
In the randomized trial, patients with the condition, familial adenomatous polyposis (FAP), who took erlotinib (Tarceva®) and sulindac (Aflodac®) had far fewer precancerous polyps in the duodenum—the first section of the small intestine, just beyond the stomach—than patients who took placebo. The benefit was so pronounced that the trial was stopped early, after only two-thirds of the planned number of participants had completed treatment.
Results from a recent clinical trial show that adjuvant therapy with sunitinib (Sutent®) or sorafenib (Nexavar®) does not improve progression-free survival for patients with renal cell (kidney) cancer and may cause serious side effects.
Findings from the randomized, double-blind, placebo-controlled trial were published March 8 in The Lancet.
Researchers have developed and tested a new injectable nanoparticle-generating technology that can deliver doxorubicin (Adriamycin®), a commonly used chemotherapy drug, straight to the nucleus of metastatic breast cancer cells with high effectiveness.
In the study, the treatment approach led to complete remissions in mice with a hard-to-treat form of breast cancer. The findings appeared in Nature Biotechnology on March 14. The research team that led the study hopes to start testing the treatment in human clinical trials by the end of 2017.
A form of chronic lymphocytic leukemia
Study found a 23 percent increased risk compared to men who received other treatments, but overall risk relatively low
Based on the results of a new study, NCI is launching a clinical program called ClinOmics, which will use genomic approaches to help guide the treatment of patients with cancer who are treated at the NIH Clinical Center.
In this interview, Javed Khan, M.D., of NCI’s Center for Cancer Research (CCR), discusses the promise and the challenges of genome-based therapy for children and adults with cancer.
A fact sheet about research on electric and magnetic fields and studies examining their potential connection with cancer.
A deficiency in vitamin D is associated with tumor progression and metastasis in breast cancer, suggests a new study.
The study, primarily conducted using cell lines and mice, also identified an association between vitamin D levels and the expression of ID1, an oncogene that has been associated with tumor growth and metastasis in breast cancer and other cancer types.